Prevelance of Common YMDD Motif Mutations in Long Term Treated Chronic HBV Infections in a Turkish Population |
Alagozlu, Hakan
(Department of Gastroenterology, Faculty of Medicine, Cumhuriyet University)
Ozdemir, Ozturk (Department of Medical Genetics, Faculty of Medicine, Canakkale Onsekiz Mart University) Koksal, Binnur (Department of Medical Genetics, Faculty of Medicine, Cumhuriyet University) Yilmaz, Abdulkerim (Department of Gastroenterology, Faculty of Medicine, Cumhuriyet University) Coskun, Mahmut (Department of Medical Biology, Faculty of Medicine, Canakkale Onsekiz Mart University) |
1 | Agca H, Sayiner AA, Sengonul A et al., (2011). A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations. Mikrobiyol Bul, 45, 664-76. |
2 | Allen MI, Deslauriers M, Andrews CW, et al (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 27, 1670-7. DOI ScienceOn |
3 | Angus P, Vaughan R, Xiong S, et al (2003). Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology, 125, 292-7. DOI ScienceOn |
4 | Aspinall EJ, Hawkins G, Fraser A, et al (2011). Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond), 61, 531-40. DOI ScienceOn |
5 | Balzarini J, Wedgwood O, Kruining J, et al (1996). Anti-HIV and anti-HBV activity and resistance profile of 3TC and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun, 2, 363-9. |
6 | Bartholomeusz A, Locarnini SA (2006). Antiviral drug resistance: clinical consequences consequences and molecular aspects. Semin Liver Dis, 26, 162-70. DOI ScienceOn |
7 | Baumert TF, Rogers SA, Hasegawa K, Liang TJ (1996). Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest, 98, 2268-76. DOI ScienceOn |
8 | Carman WF, Trautwein C, van Deursen FJ, et al (1996). Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology, 24, 489. DOI |
9 | Chen Y, Wang L, Xu H, et al (2013). Exome capture sequencing reveals new insights into hepatitis B virus-induced hepatocellular carcinoma at the early stage of tumorigenesis. Oncol Rep, 30, 1906-12. DOI |
10 | Gaillard RK, Barnard J, Lopez V, et al (2002). Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob Agents Chemother, 46, 1005-13. DOI |
11 | Chen YM, Wu SH, Qiu CN, et al (2013). Hepatitis B virus subgenotype C2- and B2-associated mutation patterns may be responsible for liver cirrhosis and hepatocellular carcinoma, respectively. Braz J Med Biol Res, 46, 614-22. DOI |
12 | Fontana RJ, Keeffe EB, Carey W, et al (2002). Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl, 8, 433-9. DOI ScienceOn |
13 | Geramizadeh B, Nikeghbalian S, Kazemi K, et al (2013). Hepatocellular carcinoma in explanted livers of patients with genotype d HBV cirrhosis: report of the first experience from Iran. Arch Iran Med, 16, 348-50. |
14 | Fung SK, Chae HB, Fontana RJ, et al (2006). Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol, 44, 283-90 DOI ScienceOn |
15 | Ganem D, Prince AM (2004). Hepatitis B virus infection− natural history and clinical consequences. N Engl J Med, 350, 1118-29. DOI ScienceOn |
16 | Gao C, Fang L, Zhao HC, et al (2013). Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection. Hepatobiliary Pancreat Dis Int, 12, 385-93. DOI ScienceOn |
17 | Guerrieri F, Belloni L, Pediconi N, Levrero M (2013). Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis, 33, 147-56. DOI ScienceOn |
18 | Gwak GY, Lee CY, Lee DH, et al (2011). Clinical impact of the development of YMDD mutants in hepatitis B virusassociated glomerulonephritis. Hepatogastroenterology, 58, 1291-5. DOI ScienceOn |
19 | Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al (2006). Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis b for up to 5 years. Gastroenterology, 131, 1743-51. DOI ScienceOn |
20 | Johnson MS, McClure MA, Feng DF, et al (1986). Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci USA, 83, 7648-52. DOI ScienceOn |
21 | Lavarone M, Colombo M (2013). HBV infection and hepatocellular carcinoma. Clin Liver Dis, 17, 375-97. DOI ScienceOn |
22 | Kim HJ, Park JH, Park DI, et al (2012). The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment. Liver Int, 32, 303-10. DOI ScienceOn |
23 | Kohlstaedt LA, Wang J, Friedman JM, et al (1992). Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-90. DOI ScienceOn |
24 | Lai CL, Chien RN, Leung NW, et al (1998). A one year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med, 339, 61-8. DOI ScienceOn |
25 | Lee CZ, Lee HS, Huang GT, et al (2006). Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol, 12, 5301-5. DOI |
26 | Lee SH, Kim HS, Byun IS, et al (2012). Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol, 84, 217-22. DOI ScienceOn |
27 | Lee YS, Suh DJ, Lim YS, et al (2006). Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 43, 1385-91. DOI ScienceOn |
28 | Li D, Cheng H, Gong W, et al (2013). Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization. J Virol Methods, 187, 259-63. DOI ScienceOn |
29 | Lin CL, Kao JH (2008). Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci, 15, 137-45. DOI |
30 | Liu K, Hou W, Zumbika E, Ni Q (2005). Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Science B, 6, 1182-8. DOI ScienceOn |
31 | Markowitz JS, Martin P, Conrad AJ, et al (1998). Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatolog, 28, 585-9. DOI ScienceOn |
32 | Matsuda M, Suzuki F, Suzuki Y, et al (2004). YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol, 74, 361-6. DOI ScienceOn |
33 | Mello FC, Lago BV, Lewis-Ximenez LL, et al (2012). Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol, 12, 96. DOI |
34 | Ogata N, Fujii K, Takigawa S, et al (1999). Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol, 59, 270-6. DOI |
35 | Poch O, Sauvaget I, Delarue M, Tordo N (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J, 8, 3867-74. |
36 | Sarma MP, Asim M, Medhi S, et al (2012). Viral genotypes and associated risk factors of hepatocellular carcinoma in India. Cancer Biol Med, 9, 172-81. |
37 | Sato S, Suzuki K, Akahane Y, et al (1995). Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med, 122, 241-8. DOI ScienceOn |
38 | Schildgen O, Sirma H, Funk A, et al (2006). Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med, 354, 1807-12. DOI ScienceOn |
39 | Singh S, Singh PP, Roberts LR, Sanchez W (2013). Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, [Epub ahead of print]. |
40 | Schildgen V, Ziegler S, Tillmann RL, Schildgen O (2010). Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case. Virol J, 7, 167. DOI ScienceOn |
41 | Tan YW, Ge GH, Zhao W, et al (2012). YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis, 16, 250-5. DOI ScienceOn |
42 | Vassiliadis T, Nikolaidis N, Giouleme O, et al (2005). Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther, 21, 531-7. DOI ScienceOn |
43 | Villamil FG (2002). Hepatitis B progress in the last 15 years. Liver Transpl, 8, 59-66. DOI ScienceOn |
44 | Wang LL, Yu XJ, Dong QJ, et al (2012). HBV genotypes distribution and YMDD spontaneous mutation in Qingdao population. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 26, 250-2. |
45 | Wu F, Wu MJ, Zhuge XL et al (2012). Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int, 11, 172-6. DOI ScienceOn |
46 | Yang JH, Zhang H, Chen XB, et al (2013). Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol, 19, 3861-5. DOI ScienceOn |
47 | Zhao J, Guo Y, Yan Z, et al (2012). The natural YMDD mutations of hepatitis B virus in Western China. Scand J Infect Dis, 44, 44-7. DOI ScienceOn |
![]() |